A levitating tattoo in a hepatitis C patient on treatment.
Atluri
Dileep
D
MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH, USA.
Iduru
Satish
S
Veluru
Chandra
C
Mullen
Kevin
K
D000998:Antiviral Agents / Q000627:therapeutic use; D001707:Biopsy, Needle; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment; D012507:Sarcoidosis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D012871:Skin Diseases / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D013256:Steroids / Q000627:therapeutic use; D013653:Tattooing / Q000009:adverse effects*; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013256:Steroids; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a